Hemato Oncology Testing Market Analysis

Product & Service (Instruments, Kits & Reagents, Software & Services)

In hemato oncology testing market, kits & reagents segment is projected to hold revenue share of more than 41.3% by 2037. For instance, in 2021, F. Hoffmann-La Roche AG announced the launch of the AVENIO tumor tissue comprehensive genomic profiling (CGP) kit. This is an expansion of the company in the personalized cancer research segment for better care and effective clinical decision-making. Furthermore, the increasing cases of blood cancers augment the need for accurate diagnostic solutions including, kits and reagents. In addition, the ongoing research in hemato oncology including clinical trials and studies and rising demand for testing kits and reagents in both academic and commercial labs are expected to boost segment growth during the forecast period.

Cancer Type (Leukemia, Lymphoma)

By 2037, lymphoma segment is anticipated to dominate hemato oncology testing market share of over 52.1% owing to high prevalence of Hodgkin lymphoma and non-Hodgkin lymphoma worldwide. The World Cancer Research Fund International estimated that in 2022, around 82,469 new Hodgkin lymphoma cases were detected worldwide. Also, the American Cancer Society anticipates that about 80,620 Americans are expected to be diagnosed with non-Hodgkin lymphoma in 2024. Understanding the importance of hemato oncology cancer care, many public and private research organizations are initiating diagnostic and awareness programs. For instance, the 15^th of September each year is celebrated as World Lymphoma Awareness Day.

Our in-depth analysis of the market includes the following segments: